European guideline for the diagnosis and treatment of insomnia

Journal of Sleep Research

Volumn 26, Issue 6, 2017, Pages 675-700

  Riemann, Dieter ^a   Baglioni, Chiara ^a   Bassetti, Claudio ^b   Bjorvatn, Bjørn ^c   Dolenc Groselj, Leja ^d   Ellis, Jason G ^e   Espie, Colin A ^f   Garcia Borreguero, Diego ^g   Gjerstad, Michaela ^h   Gonçalves, Marta ⁱ   Hertenstein, Elisabeth ^a   Jansson Fröjmark, Markus ^j   Jennum, Poul J ^k   Leger, Damien ^l   Nissen, Christoph ^a,b   Parrino, Liborio ^m   Paunio, Tiina ⁿ   Pevernagie, Dirk ^o   Verbraecken, Johan ^p   Weeß, Hans Günter ^q   Wichniak, Adam ^r   Zavalko, Irina ^s   Arnardottir, Erna S ^t   Deleanu, Oana Claudia ^u   Strazisar, Barbara ^v   Zoetmulder, Marielle ^w   Spiegelhalder, Kai ^a   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^e NORTHUMBRIA UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g SLEEP RESEARCH INSTITUTE   (Spain)

^h STAVANGER UNIVERSITY HOSPITAL   (Norway)

ⁱ CUF Hospital   (Portugal)

^j KAROLINSKA INSTITUTE   (Sweden)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m UNIVERSITY OF PARMA   (Italy)

ⁿ NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^o EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^p ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^q Sleep Center Pfalzklinikum   (Germany)

^r INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^s INSTITUTE OF BIOPHYSICS   (Russian Federation)

^t LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^u UNIVERSITY OF BUCHAREST   (Romania)

^v General Hospital Celje   (Slovenia)

^w FREDERIKSBERG HOSPITAL   (Denmark)

more..

Author keywords

CBT I; evidence based medicine; hypnotics

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; HYPNOTIC AGENT; ANTIHISTAMINIC AGENT; MELATONIN; NEUROLEPTIC AGENT;

ALTERNATIVE MEDICINE; ARTICLE; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE THERAPY; COMORBIDITY; CONFUSION; CONSENSUS DEVELOPMENT; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; EXERCISE; FATIGUE; HANGOVER; HEALTH CARE COST; HEALTH HAZARD; HUMAN; INSOMNIA; LONG TERM CARE; PATHOPHYSIOLOGY; PHOTOTHERAPY; POLYSOMNOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAXATION TRAINING; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; ADULT; DRUG EFFECTS; EUROPE; FEMALE; MALE; METABOLISM; SLEEP;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITIVE THERAPY; COMORBIDITY; COMPLEMENTARY THERAPIES; EUROPE; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MELATONIN; PHOTOTHERAPY; POLYSOMNOGRAPHY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 85035020111     PISSN: 09621105     EISSN: 13652869     Source Type: Journal    
DOI: 10.1111/jsr.12594     Document Type: Article

References (241)

1. Abbott, S. M., Reid, K. J. and Zee, P. C. Circadian disorders of the sleep-wake cycle. In: M. Kryger, T. Roth and W. C. Dement (Eds) Principles and Practice of Sleep Medicine. Elsevier, Philadelphia, 2016: 414–423.
2. ACP. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med., 2016, 165: 125–133.
3. Ancoli-Insrael, S., Krystal, A. D., McCall, W. V. et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep, 2010, 33: 225–234.
4. Anderson, S. L. and Vande Griend, J. P. Quetiapine for insomnia: a review of the literature. Am. J. Health Syst. Pharm., 2014, 71: 394–402.
5. Anothaisintawee, T., Reutrakul, S., Van Cauter, E. and Thakkinstian, A. Sleep disturbances compared to traditional risk factors for diabetes development: systematic review and meta-analysis. Sleep Med. Rev., 2015, 30: 11–24.
6. Atkins, D., Best, D., Briss, P. A. et al. Grading quality of evidence and strength of recommendations. BMJ, 2004, 328: 1490–1494.
7. Backhaus, J. and Riemann, D. Poruchy Spanku. Hogrefe Verlag, Slovakian edition, Trencin, 2003.
8. Baglioni, C., Spiegelhalder, K., Lombardo, C. and Riemann, D. Sleep and emotions: a focus on insomnia. Sleep Med. Rev., 2010, 14: 227–238.
9. Baglioni, C., Battagliese, G., Feige, B. et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J. Affect. Disord., 2011, 135: 10–19.
10. Baglioni, C., Regen, W., Teghen, A. et al. Sleep changes in the disorder of insomnia: a meta-analysis of polysomnographic studies. Sleep Med. Rev., 2014, 18: 195–213.
11. Baglioni, C., Nanovska, S., Regen, W. et al. Sleep and mental disorders: a meta-analysis of polysomnographic research. Psychol. Bull., 2016, 142: 969–990.
12. Barker, M. J., Greenwood, K. M., Jackson, M. and Crowe, S. F. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch. Clin. Neuropsychol., 2004, 19: 437–454.
13. Bassetti, C., Ferini-Strambi, L., Adamantidis, A. et al. Neurology and psychiatry: waking up to the opportunities of sleep. Eur. J. Neurol., 2015, 10: 1337–1354.
14. Bastien, C. H., Vallières, A. and Morin, C. M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med., 2001, 2: 297–307.
15. Bayon, V., Léger, D., Gomez-Merino, N., Vecchierini, M. F. and Chennaoui, M. Sleep debt and obesity. Ann. Med., 2014, 46: 264–272.
16. Bélanger, L., Vallières, A., Ivers, H., Moreau, V., Lavigne, G. and Morin, C. M. Meta-analysis of sleep changes in control groups of insomnia treatment trials. J. Sleep Res., 2007, 16: 77–84.
17. Belleville, G., Cousineau, H., Levrier, K. and St. Pierre-Delorme, M. E. Meta-analytic review of the impact of cognitive-behavior therapy for insomnia on concomitant anxiety. Clin. Psychol. Rev., 2011, 31: 638–652.
18. Bent, S., Padula, A., Moore, D., Patterson, M. and Mehling, W. Valerian for sleep: a systematic review and meta-analysis. Am. J. Med., 2006, 119: 1005–1012.
19. Bjorvatn, B. En Handbook til deg som Sover Darlig. 2 uitgave. Fakbokforlaget, Oslo, 2013.
20. Bjorvatn, B., Meland, E., Flo, E. and Mildestvedt, T. High prevalence of insomnia and hypnotic use in patients visiting their general practitioner. Fam. Pract., 2017, 34: 20–24.
21. Bootzin, R. R. Stimulus control treatment for insomnia. Proc. Am. Psychol. Assoc., 1972, 7: 395–396.
22. Borbély, A. A. A two process model of sleep regulation. Hum. Neurobiol., 1982, 1: 195–204.
23. Borbély, A. A. and Achermann, P. Sleep homeostasis and models of sleep regulation. J. Biol. Rhythms, 1999, 14: 557–568.
24. Braam, W., Smits, M. G., Didden, R., Korzilius, H., van Geijlswijk, I. M. and Curfs, L. M. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis. Dev. Med. Child Neurol., 2009, 51: 340–349.
25. Brzezinski, A., Vangel, M. G., Wurtman, R. J. et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med. Rev., 2005, 9: 41–50.
26. Buscemi, N., Vandermeer, B., Hooton, N. et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J. Gen. Intern. Med., 2005, 20: 1151–1158.
27. Buscemi, N., Vandermeer, B., Hooton, N. et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ, 2006, 332: 385–393.
28. Buscemi, N., Vandermeer, B., Friesen, C. et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J. Gen. Intern. Med., 2007, 22: 1335–1350.
29. Buxton, O. M. and Marcelli, E. Short and long sleep are positively associated with obesity, diabetes, hypertension, and cardiovascular disease among adults in the United States. Soc. Sci. Med., 2010, 71: 1027–1036.
30. Buysse, D. J., Reynolds, C. F. 3rd, Monk, T. H., Berman, S. R. and Kupfer, D. J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res., 1989, 28: 193–213.
31. Buysse, D. J., Germain, A., Moul, D. E. et al. Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch. Intern. Med., 2011, 171: 887–895.
32. Calem, M., Bisla, J., Begum, A. et al. Increased prevalence of insomnia and changes in hypnotic use in England over 15 years: analysis of the 1993, 2000 and 2007 national psychiatric morbidity surveys. Sleep, 2012, 35: 377–384.
33. Cao, H., Pan, X., Li, H. and Liu, J. Acupuncture for treatment of insomnia: a systematic review of randomized controlled trials. J. Altern. Complement. Med., 2009, 15: 1171–1186.
34. Cappuccio, F. P., D'Elia, L., Strazzullo, P. and Miller, M. A. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care, 2010, 33: 414–420.
35. Carney, C. E., Buysse, D. J., Ancoli-Israel, S. et al. The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep, 2012, 35: 287–302.
36. Chen, H. Y. and Shi, Y. NG, CS, Chan, SM, Yung, KK, Zhang, QL: Auricular acupuncture treatment for insomnia: a systematic review. J Altern Complement Med, 2007, 13: 669–676.
37. Cheng, S. K. and Dizon, J. Computerised cognitive behavioural therapy for insomnia: a systematic review and meta-analysis. Psychother. Psychosom., 2012, 81: 206–216.
38. Cheuk, D. K., Yeung, W. F., Chung, K. F. and Wong, V. Acupuncture for insomnia. Cochrane Database Syst. Rev., 2012, 9: CD005472.
39. Chouvarda, I., Oswaldo-Mendez, M., Rosso, V. et al. Cyclic alternating patterns in normal sleep and insomnia: structure and content differences. IEEE Trans. Neural Syst. Rehabil. Eng., 2012, 20: 642–652.
40. Christensen, H., Batterham, P. J., Gosling, J. A. et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight study): a randomised controlled trial. Lancet Psychiatry, 2016, 3: 333–341.
41. Cohrs, S. Sleep disturbances in patients with schizophrenia: impact and effects of antipsychotics. CNS Drugs, 2008, 22: 939–962.
42. Collins, P. Y., Patel, V., Joestl, S. S. et al. Grand challenges in global mental health. Nature, 2011, 475: 27–30.
43. Cooper, K. L. and Relton, C. Homeopathy for insomnia: a systematic review of research evidence. Sleep Med. Rev., 2010, 14: 329–337.
44. Crane, R. S., Brewer, J., Feldman, C. et al. What defines mindfulness-based programs? The warp and the weft. Psychol. Med., 2017, 47: 990–999.
45. Daley, M., Morin, C. M., LeBlanc, M., Grégoire, J. P. and Savard, J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep, 2009, 32: 55–64.
46. Dassanayake, T., Michie, P., Carter, G. and Jones, A. Effects of benzodiazepines, antidepressants, and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf., 2011, 34: 125–156.
47. Devoto, A. and Violani, C. Curare l′Ínsonnia Senza Farmaci. Corocci Faber, Roma, 2009.
48. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, 2013.
49. Dündar, Y., Dodd, S., Strobl, J., Boland, A., Dickson, R. and Walley, T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum. Psychopharmacol., 2004, 19: 305–322.
50. Ellis, J. G., Gehrman, P., Espie, C. A., Riemann, D. and Perlis, M. L. Acute insomnia: current conceptualizations and future directions. Sleep Med. Rev., 2012a, 16: 5–14.
51. Ellis, J. G., Perlis, M. L., Neale, L., Espie, C. A. and Bastien, C. H. The natural history of insomnia: focus on prevalence and incidence of acute insomnia. J. Psychiatr. Res., 2012b, 46: 1278–1285.
52. Ellis, J. G., Cushing, T. and Germain, A. Treating acute insomnia: a randomized controlled trial of a “single-shot” of cognitive behavioral therapy for insomnia. Sleep, 2015, 38: 971–978.
53. Ernst, E., Lee, M. S. and Choi, T. Y. Acupuncture for insomnia? An overview of systematic reviews. Eur. J. Gen. Pract., 2011, 17: 116–123.
54. Espie, C. A. Insomnia: conceptual issues in the development, persistence and treatment of sleep disorders in adults. Annu. Rev. Psychol., 2002, 53: 215–243.
55. Espie, C. A., Broomfield, N. M., MacMahon, K. M., Macphee, L. M. and Taylor, L. M. The attention-intention-effort pathway in the development of psychophysiologic insomnia: a theoretical review. Sleep Med. Rev., 2006, 10: 215–245.
56. Espie, C. A., MacMahon, K. M. A., Kelly, H. L. et al. Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep, 2007, 30: 574–584.
57. Espie, C. A., Kyle, S. D., Williams, C. et al. A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 2012, 35: 769–781.
58. Facco, E. Meditation and hypnosis: two sides of the same coin? Int. J. Clin. Exp. Hypn., 2017, 65: 169–188.
59. Faraut, B., Touchette, E., Gamble, H. et al. Short sleep duration and increased risk of hypertension: a primary care medicine investigation. J. Hypertens., 2012, 30: 1354–1363.
60. Feige, B., Al-Shajlawi, A., Nissen, C. et al. Does REM sleep contribute to subjective wake time in primary insomnia? A comparison of polysomnographic and subjective sleep in 100 patients. J. Sleep Res., 2008, 17: 180–190.
61. Feige, B., Baglioni, C., Spiegelhalder, K., Hirscher, V., Nissen, C. and Riemann, D. The microstructure of sleep in primary insomnia: an overview and extension. Int. J. Psychophysiol., 2013, 89: 171–180.
62. Fernandez-Mendoza, J. The insomnia with short sleep duration phenotype: an update on its importance for health and prevention. Curr. Opin. Psychiatry, 2017, 30: 56–63.
63. Fernández-San-Martín, M. I., Masa-Font, R., Palacios-Soler, L., Sancho-Gómez, P., Calbó-Caldentey, C. and Flores-Mateo, G. Effectiveness of valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med., 2010, 11: 505–511.
64. Ferracioli-Oda, E., Qawasmi, A. and Bloch, M. H. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS ONE, 2013, 8: e63773.
65. Frandsen, R., Baandrup, L., Kjellberg, J., Ibsen, R. and Jennum, P. Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: a national register-based study. Parkinsonism Relat. D., 2014, 20: 1124–1128.
66. Frase, L., Piosczyk, H., Zittel, S. et al. The modulation of arousal and sleep continuity by transcranial direct current stimulation (tDCS). Neuropsychopharmacology, 2016, 41: 2577–2586.
67. Frase, L., Selhausen, P., Krone, L. et al. Transcranial direct current stimulation (tDCS) in insomnia disorder. Sleep, 2017, (submitted).
68. Geiger-Brown, J. M., Rogers, V. E., Liu, W., Ludeman, E. M., Downton, K. D. and Diaz-Abad, M. Cognitive behavioral therapy in persons with comorbid insomnia: a meta-analysis. Sleep Med. Rev., 2015, 23: 54–67.
69. Geijlswijk, I. M., Korzilius, H. P. and Smits, M. G. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep, 2010, 33: 1605–1614.
70. Glass, J., Lanctôt, K. L., Hermann, N., Sproule, B. A. and Busto, U. E. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ, 2005, 331: 1169.
71. Gong, H., Ni, C. X., Liu, Y. Z. et al. Mindfulness meditation for insomnia: a meta-analysis of randomized controlled trials. J. Psychosom. Res., 2016, 89: 1–6.
72. Goulet, J., Chaloult, L. and Ngo, T. L. Guide de pratique pour le traitement de l'insomnie. 2013. https://tccmontreal.files.wordpress.com/2014/01/guide-de-pratique-insomnie-final-21sept-2013.pdf
73. Gustavsson, A., Svensson, M., Jacobi, F. et al. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol., 2011, 21: 718–779.
74. Guyatt, G. H., Oxman, A. D., Vist, G. E. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336: 924–926.
75. Hallfors, D. D. and Saxe, L. The dependence potential of short half-life benzodiazepines: a meta-analysis. Am. J. Public Health, 1993, 83: 1300–1304.
76. Harris, J., Lack, L., Kemp, K. et al. A randomized controlled trial of intensive sleep retraining (ISR): a brief conditioning treatment for chronic insomnia. Sleep, 2012, 35: 49–60.
77. Harvey, A. G. A cognitive model of insomnia. Behav. Res. Ther., 2002, 40: 869–893.
78. Hauri, P. J. Case Studies in Insomnia. Plenum Medical Book Company, New York, 1991.
79. Hauri, P. J. and Fisher, J. Persistent psychophysiologic (learned) insomnia. Sleep, 1986, 9: 38–53.
80. Hertenstein, E., Thiel, N., Lüking, M. et al. Quality of life improvements after Acceptance and Commitment Therapy (ACT) in nonresponders to cognitive behavioral therapy for primary insomnia (CBT-I). Psychother. Psychosom., 2014, 83: 371–373.
81. Hertenstein, E., Spiegelhalder, K., Johann, A. and Riemann, D. Prävention und Psychotherapie der Insomnie. Kohlhammer, Stuttgart, 2015.
82. Ho, F. Y., Chung, K. F., Yeung, W. F. et al. Self-help cognitive-behavioral therapy for insomnia: a meta-analysis of randomized controlled trials. Sleep Med. Rev., 2015, 19: 17–28.
83. Ho, F. Y., Chan, C. S. and Tang, K. N. Cognitive-behavioral therapy for sleep disturbances in treating posttraumatic stress disorder symptoms: a meta-analysis of randomized controlled trials. Clin. Psychol. Rev., 2016, 43: 90–102.
84. Hoffmann, F. Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany. Ger. Med. Sci., 2013, 11: 1–7.
85. Holbrook, A. M., Crowther, R., Lotter, A., Cheng, C. and King, D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ, 2000, 162: 225–233.
86. Hróbjartsson, A. and Gøtzsche, P. C. Is the placebo powerless? N. Engl. J. Med., 2001, 344: 1594–1602.
87. Huck, Ü. K., Hubbard, J. and Bourgin, P. Circadian rhythm sleep disorders – treatment. In: C. Bassetti, Z. Dogas and P. Peigneux (Eds) Sleep Medicine Textbook. European Sleep Research Society, Regensburg, 2014: 357–367.
88. Huedo-Medina, T. B., Kirsch, I., Middlemass, J., Klonizakis, M. and Siriwardena, A. N. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ, 2012, 345: e8343.
89. Hupin, D., Roche, F., Gremeaux, V. et al. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged ≥60 years: a systematic review and meta-analysis. Br. J. Sports Med., 2015, 49: 1262–1267.
90. Hwang, E. and Shin, S. The effects of aromatherapy on sleep improvement: a systematic literature review and meta-analysis. J. Altern. Complement. Med., 2015, 21: 61–68.
91. ICD-10 (International Statistical Classification of Diseases and Related Health Problems). Kapitel V - F 51.0 Nichtorganische Insomnie. WHO, Hans Huber Verlag, Bern, 1992.
92. ICSD-3 (International Classification of Sleep ICSD-3 Disorders). American Association of Sleep Medicine, Dartmouth, Illinois, 2014.
93. Irwin, M. R., Cole, J. C. and Nicassio, P. M. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol., 2006, 25: 3–14.
94. Jennum, P., Baandrup, L., Ibsen, R. and Kjellberg, J. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. Eur. Neuropsychopharmacol., 2015, 25: 1906–1913.
95. Jennum, P., Baandrup, L., Iversen, H. K., Ibsen, R. and Kjellberg, J. Mortality and use of psychotropic medication in patients with stroke: a population-wide, register-based study. BMJ Open, 2016, 6: e010662. https://doi.org/10.1136/bmjopen-2015-010662.
96. Jespersen, K. V., Koenig, J., Jennum, P. and Vuust, P. Music for insomnia in adults. Cochrane Database Syst. Rev., 2015, 8: CD010459.
97. Johnson, J. A., Rash, J. A., Campbell, T. S. et al. A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. Sleep Med. Rev., 2016, 27: 20–28.
98. Joya, F. L., Kripke, D. F., Loving, R. T., Dawson, A. and Kline, L. E. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J. Clin. Sleep Med., 2009, 5: 377–383.
99. Kanen, J. W., Nazir, R., Sedky, K. and Pradhan, B. K. The effects of mindfulness-based interventions on sleep disturbance: a meta-analysis. Adolesc. Psychiatry, 2015, 5: 105–115.
100. Kapil, V., Green, J. L., Le Lait, C., Wood, D. M. and Dargan, P. I. Misuse of benzodiazepines and Z-drugs in the UK. Br. J. Psychiatry, 2014, 205: 407–408.
101. Koffel, E. A., Koffel, J. B. and Gehrman, P. R. A meta-analysis of group cognitive behavioral therapy for insomnia. Sleep Med. Rev., 2015, 19: 6–16.
102. Kredlow, M. A., Capozzoli, M. C., Hearon, B. A., Calkins, A. W. and Otto, M. W. The effects of physical activity on sleep: a meta-analytic review. J. Behav. Med., 2015, 38: 427–449.
103. Kripke, D. F. Do hypnotics cause death and cancer? The burden of proof Sleep Med., 2009, 10: 275–276.
104. Kripke, D. F. Is insomnia associated with mortality? Sleep, 2011, 34: 555.
105. Kripke, D. F. Surprising view of insomnia and sleeping pills. Sleep, 2013, 36: 1127–1128.
106. Kripke, D. F., Simons, R. N., Garfinkel, L. and Hammond, E. C. Short and long sleep and sleeping pills. Is increased mortality associated? Arch. Gen. Psychiatry, 1979, 36: 103–116.
107. Kripke, D. F., Garfinkel, L., Wingard, D. L., Klauber, M. R. and Marler, M. R. Mortality associated with sleep duration and insomnia. Arch. Gen. Psychiatry, 2002, 59: 131–136.
108. Krystal, A. D., Walsh, J. K., Laska, E. et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 2003, 26: 793–799.
109. Krystal, A. D., Erman, M., Zammit, G. K., Soubrane, C. and Roth, R. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep, 2008, 31: 79–90.
110. Krystal, A. D., Durrence, H. H., Scharf, M. et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep, 2010, 33: 1553–1561.
111. Kuriyama, A., Honda, M. and Hayashino, Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med., 2014, 15: 385–392.
112. Kyle, S. D., Morgan, K., Spiegelhalder, K. and Espie, C. A. No pain, no gain: an exploratory within-subjects mixed-methods evaluation of the patient experience of sleep restriction therapy (SRT) for insomnia. Sleep Med., 2011, 12: 735–747.
113. Kyle, S. D., Miller, C. B., Rogers, Z., Siriwardena, A. N., MacMahon, K. M. and Espie, C. A. Sleep restriction therapy for insomnia is associated with reduced objective total sleep time, increased daytime somnolence, and objectively impaired vigilance: implications for the clinical management of insomnia disorder. Sleep, 2014, 37: 229–237.
114. Kyle, S. D., Aquino, M. R., Miller, C. V. et al. Towards standardization and improved understanding of sleep restriction therapy for insomnia disorder: a systematic examination of CBT-I trial content. Sleep Med. Rev., 2015, 23: 83–88.
115. Lam, T. H., Chung, K. F., Yeung, W. F., Yu, B. Y., Yung, K. P. and Ng, T. H. Hypnotherapy for insomnia: a systematic review and meta-analysis of randomized controlled trials. Complement. Ther. Med., 2015, 23: 719–732.
116. Lan, Y., Wu, X., Tan, H. J. et al. Auricular acupuncture with seed or pellet attachments for primary insomnia: a systematic review and meta-analysis. BMC Complement Altern. Med., 2015, 15: 103.
117. Laugsand, L. E., Vatten, L. J., Platou, C. and Janszky, I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation, 2011, 124: 2073–2081.
118. Laugsand, L. E., Strand, L. B., Platou, C., Vatten, L. J. and Janszky, I. Insomnia and the risk of incident heart failure: a population study. Eur. Heart J., 2014a, 35: 1382–1393.
119. Laugsand, L. E., Strand, L. B., Vatten, L. J., Janszky, I. and Bjørngaard, J. H. Insomnia symptoms and risk for unintentional fatal injuries - the HUNT Study. Sleep, 2014b, 37: 1777–1786.
120. Leach, M. J. and Page, A. T. Herbal medicine for insomnia: a systematic review and meta-analysis. Sleep Med. Rev., 2015, 24: 1–12.
121. Lee, S. H. and Lim, S. M. Acupuncture for insomnia after stroke: a systematic review and meta-analysis. BMC Complement Altern. Med., 2016, 16: 228.
122. Lee, J., Han, M., Chung, Y., Kim, J. and Choi, J. Effects of foot reflexology on fatigue, sleep and pain: a systematic review and meta-analysis. J. Korean Acad. Nurs., 2011, 41: 821–833.
123. Léger, D. and Bayon, V. Societal costs of insomnia. Sleep Med. Rev., 2010, 14: 379–389.
124. Léger, D., Guilleminault, C., Dreyfus, J. P., Delahaye, C. and Paillard, M. Prevalence of insomnia in a survey of 12 778 adults in France. J. Sleep Res., 2000, 9: 35–42.
125. Léger, D., Bayon, V., Ohayon, M. M. et al. Insomnia and accidents: cross sectional study (EQUINOX) on sleep-related home, work and car accidents in 5293 subjects with insomnia from ten countries. J. Sleep Res., 2014, 23: 143–152.
126. Levenson, J. C., Kay, D. B. and Buysse, D. J. The pathophysiology of insomnia. Chest, 2015, 147: 1179–1192.
127. Li, M., Zhang, X. W., Hou, W. S. and Tang, Z. Y. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int. J. Cardiol., 2014, 176: 1044–1047.
128. Lillehei, A. S. and Halcon, L. L. A systematic review of the effect of inhaled essential oils on sleep. J. Altern. Complement. Med., 2014, 20: 441–451.
129. Liu, J. and Wang, L. N. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int. J. Clin. Pract., 2012, 66: 867–873.
130. Liu, T. Z., Xu, C., Rota, M. et al. Sleep duration and risk of all-cause mortality: a flexible, non-linear, meta-regression of 40 prospective cohort studies. Sleep Med. Rev., 2017, 32: 28–36.
131. Malik, S., Kanwar, A., Sim, L. A. et al. The association between sleep disturbances and suicidal behaviors in patients with psychiatric diagnoses: a systematic review and meta-analysis. Syst. Rev., 2014, 3: 18.
132. Mallon, L., Broman, J. E., Akerstedt, T. and Hetta, J. Insomnia in Sweden: a population-based survey. Sleep Disord., 2014, 2014: 843126.
133. Marschall, J., Hildebrandt, S., Sydow, H. and Nolting, H. D. Gesundheitsreport 2017 (DAK Report). Medhochzwei Verlag, Heidelberg, 2017.
134. Mayer, G., Wang-Weigand, S., Roth-Schechter, B., Lehmann, R., Staner, C. and Partinen, M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep, 2009, 32: 351–360.
135. Mayer, G., Jennum, P., Riemann, D. and Dauvilliers, Y. Insomnia in central neurologic diseases – occurrence and management. Sleep Med. Rev., 2011, 15: 369–378.
136. McCall, W. V., D'Agostino, R. Jr and Dunn, A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med., 2003, 4: 57–62.
137. McCleery, J., Cohen, D. A. and Sharpley, A. L. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst. Rev., 2014, 3: CD009178.
138. Meng, L., Zheng, Y. and Hui, R. The relationship of sleep duration and insomnia to risk of hypertension incidence: a meta-analysis of prospective cohort studies. Hypertens. Res., 2013, 36: 985–995.
139. Michelson, D., Snyder, E., Paradis, E. et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol., 2014, 13: 461–471.
140. Miller, C. B., Espie, C. A., Epstein, D. R. et al. The evidence base of sleep restriction therapy for treating insomnia disorder. Sleep Med. Rev., 2014, 18: 415–424.
141. Mitchell, M. D., Gehrman, P., Perlis, M. and Umscheid, C. A. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam. Pract., 2012, 13: 40.
142. Montgomery, P. and Dennis, J. A systematic review of non-pharmacological therapies for sleep problems in later life. Sleep Med. Rev., 2004, 8: 47–62.
143. Monti, J. M. and Monti, D. Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med. Rev., 2004, 8: 133–148.
144. Monti, J., Torterolo, P. and Pandi-Perumal, S. R. The effects of second generation antipsychotics in healthy subjects and patients with schizophrenia. Sleep Med. Rev., 2017, 33: 51–57.
145. Morin, C. M. Insomnia. Guildford Press, New York, 1993.
146. Morin, C. M. and Espie, C. A. Insomnia – A Clinical Guide to Assessment and Treatment. Springer, New York, 2004.
147. Morin, C. M., Culbert, J. P. and Schwartz, S. M. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am. J. Psychiatry, 1994, 151: 1172–1180.
148. Morin, C. M., Colecchi, C., Stone, J., Sood, R. and Brink, D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA, 1999, 281: 991–999.
149. Morin, C. M., Bélanger, L., LeBlanc, M. et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch. Intern. Med., 2009a, 169: 447–453.
150. Morin, C. M., Vallières, A., Guay, B. et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA, 2009b, 301: 2005–2015.
151. Murtagh, D. R. and Greenwood, K. M. Identifying effective psychological treatments for insomnia: a meta-analysis. J. Consult. Clin. Psychol., 1995, 63: 79–89.
152. National Institutes of Health. National Institutes of Health State of the Science Conference Statement on Manifestations and management of chronic insomnia in adults June 13–15, 2005. Sleep, 2005, 28: 1049–1057.
153. Ni, X., Shergis, J. L., Guo, X. et al. Updated clinical evidence of Chinese herbal medicine for insomnia: a systematic review and meta-analysis of randomized controlled trials. Sleep Med., 2015, 16: 1462–1481.
154. de Niet, G., Tiemens, B., Lendemeijer, B. and Hutschemaekers, G. Music-assisted relaxation to improve sleep quality: meta-analysis. J. Adv. Nurs., 2009, 65: 1356–1364.
155. Nofzinger, E. and Buysse, D. J. Frontal cerebral thermal transfer as a treatment for insomnia: a dose-ranging study. Sleep, 2011, 34. Abstract Supplement: A0534.
156. Novak, M., Mucsi, I., Shapiro, C. M., Rethelyi, J. and Kopp, M. S. Increased utilization of health services by insomniacs – an epidemiological perspective. J. Psychosom. Res., 2004, 56: 527–536.
157. Nowell, P. D., Mazumdar, S., Buysse, D. J., Dew, M. A., Reynolds, C. F. 3rd and Kupfer, D. J. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA, 1997, 278: 2170–2177.
158. Ohayon, M. M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med. Rev., 2002, 6: 97–111.
159. Ohayon, M. M. and Partinen, M. Insomnia and global sleep dissatisfaction in Finland. J. Sleep Res., 2002, 11: 339–346.
160. Ohayon, M. M. and Sagales, T. Prevalence of insomnia and sleep characteristics in the general population of Spain. Sleep Med., 2010, 11: 1010–1018.
161. Ohayon, M. M. and Smirne, S. Prevalence and consequences of insomnia disorders in the general population of Italy. Sleep Med., 2002, 3: 115–120.
162. Okajima, I., Komada, Y. and Inoue, Y. A meta-analysis on the treatment effectiveness of cognitive behavioral therapy for primary insomnia. Sleep Biol. Rhythms, 2011, 9: 24–34.
163. Osorio, R. S., Pirraglia, E., Agüera-Ortiz, L. F. et al. Greater risk of Alzheimer's disease in older adults with insomnia. J. Am. Geriatr. Soc., 2011, 59: 559–562.
164. Ozminkowski, R. J., Wang, S. and Walsh, J. K. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep, 2007, 30: 263–273.
165. Paiva, T. Bom Sono, boa Vida. Officina do Livro. Cruz Quebrada, Lisboav, 2008.
166. Palagini, L., Bruno, R. M., Gemignani, A., Baglioni, C., Ghiadoni, L. and Riemann, D. Sleep loss and hypertension: a systematic review. Curr. Pharm. Des., 2013, 19: 2409–2419.
167. Palagini, L., Biber, K. and Riemann, D. The genetics of insomnia – evidence for epigenetic mechanisms? Sleep Med. Rev., 2014, 18: 225–235.
168. Pallesen, S., Nordhus, I. H. and Kvale, G. Nonpharmacological interventions for insomnia in older adults: a meta-analysis of treatment efficacy. Psychother. Theory Res. Pract. Train., 1998, 35: 472–482.
169. Pallesen, S., Nordhus, I. H., Nielsen, G. H. et al. Prevalence of insomnia in the adult Norwegian population. Sleep, 2001, 24: 771–779.
170. Pallesen, S., Bjorvatn, B., Nordhus, I. H., Sivertsen, B., Hjornevik, M. and Morin, C. M. A new scale for measuring insomnia: the bergen insomnia scale. Percept. Mot. Skills, 2008, 107: 691–706.
171. Pallesen, S., Sivertsen, B., Nordhus, I. H. and Bjorvatn, B. A 10-year trend of insomnia prevalence in the adult norwegian population. Sleep Med., 2014, 15: 173–179.
172. Palmaro, A., Dupouy, J. and Lapeyre-Mestre, M. Benzodiazepines and risk of death: results from two large cohort studies in France and UK. Eur. Neuropsychopharmacol., 2015, 25: 1566–1577.
173. Parrino, L., Smerieri, A., Giglia, F., Milioli, G., De Paolis, F. and Terzano, M. G. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clin. Neuropsychopharmacol., 2008, 31: 40–50.
174. Patel, S. R. and Hu, F. B. Short sleep duration and weight gain: a systematic review. Obesity, 2008, 16: 643–653.
175. Paunio, T., Korhonen, T., Hublin, C. et al. Poor sleep predicts symptoms of depression and disability retirement due to depression. J. Affect. Disord., 2015, 172: 381–389.
176. Perlis, M. L., Giles, D. E., Mendelson, W. B., Bootzin, R. R. and Wyatt, J. K. Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. J. Sleep Res., 1997, 6: 179–188.
177. Perlis, M. L., McCall, W. V., Krystal, A. D. and Walsh, J. K. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J. Clin. Psychiatry, 2004, 65: 1128–1137.
178. Perlis, M. L., Jungquist, C., Smith, M. T. and Posner, D. Cognitive Behavioral Treatment of Insomnia. Springer, New York, 2005.
179. Pigeon, W. R., Pinquart, M. and Conner, K. Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J. Clin. Psychiatry, 2012, 73: 1160–1167.
180. Pillai, V., Roth, T., Roehrs, T., Moss, K., Peterson, E. L. and Drake, C. L. Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: an examination of response and remission rates. Sleep, 2017;40 doi: 10.1093/sleep/zsw044
181. Randall, S., Roehrs, T. A. and Roth, T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep, 2012, 35: 1551–1557.
182. Rapoport, M. J., Lanctot, K. L., Streiner, D. L. et al. Benzodiazepine use and driving: a meta-analysis. J. Clin. Psychiatry, 2009, 70: 663–673.
183. Riemann, D. and Nissen, C. Sleep and psychotropic drugs. In: C. M. Morin and C. A. Espie (Eds) Oxford Handbook of Sleep and Sleep Disorders. Oxford University Press, Oxford, 2012: 190–222.
184. Riemann, D. and Perlis, M. L. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med. Rev., 2009, 13: 205–214.
185. Riemann, D. and Voderholzer, U. Primary insomnia: a risk factor to develop depression? J. Affect. Disord., 2003, 76: 255–259.
186. Riemann, D., Spiegelhalder, K., Feige, B. et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med. Rev., 2010, 14: 19–31.
187. Riemann, D., Spiegelhalder, K., Nissen, C., Hirscher, V., Baglioni, C. and Feige, B. REM sleep instability – a new pathway for insomnia? Pharmacopsychiatry, 2012, 45: 167–176.
188. Riemann, D., Nissen, C., Palagini, L., Otte, A., Perlis, M. L. and Spiegelhalder, K. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol., 2015, 14: 547–558.
189. Riemann, D., Baum, E., Cohrs, S. et al. S-3 Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Kapitel Insomnie bei Erwachsenen (AWMF Registriernummer 063-003), Update 2016. Somnologie, 2017, 20: 2–44.
190. Ritterband, L. M., Thorndike, F. P., Gonder-Frederick, L. A. et al. Efficacy of an internet-based behavioral intervention for adults with insomnia. Arch. Gen. Psychiatry, 2009, 66: 692–698.
191. Roehrs, T. A., Randall, S., Harris, E., Maan, R. and Roth, T. Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study. Sleep, 2011, 34: 207–212.
192. Roth, T., Walsh, J. K., Krystal, A., Wessel, T. and Roehrs, T. A. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med., 2005, 6: 487–495.
193. Saper, C. B., Scammell, T. E. and Lu, J. Hypothalamic regulation of sleep and circadian rhythms. Nature, 2005, 437: 1257–1263.
194. Sarris, J. and Byrne, G. J. A systematic review of insomnia and complementary medicine. Sleep Med. Rev., 2011, 15: 99–106.
195. Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. and Heald, J. L. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J. Clin. Sleep Med., 2017, 13: 307–349.
196. Schlack, R., Hapke, U., Maske, U., Busch, M. and Cohrs, S. Häufigkeit und Verteilung von Schlafproblemen und Insomnie in der deutschen Erwachsenenbevölkerung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2013, 56: 740–748.
197. Sexton, C. E., Storsve, A. B., Walhovd, K. B., Johansen-Berg, H. and Fjell, A. M. Poor sleep quality is associated with increased cortical atrophy in community-dwelling adults. Neurology, 2014, 83: 967–973.
198. Seyffert, M., Lagisetty, P., Landgraf, J. et al. Internet-delivered cognitive behavioral therapy to treat insomnia: a systematic review and meta-analysis. PLoS ONE, 2016, 11: e0149139.
199. Shahid, A., Wilkinson, K., Marcu, S. and Shapiro, C. M. STOP, THAT and One Hundred Other Sleep Scales. Springer, New York, 2012.
200. Sivertsen, B., Øverland, S., Pallesen, S. et al. Insomnia and long sleep duration are risk factors for later work disability. The Hordaland Health Study. J. Sleep Res., 2009a, 18: 122–128.
201. Sivertsen, B., Øverland, S., Bjorvatn, B., Maeland, J. G. and Mykletun, A. Does insomnia predict sick leave? The Hordaland Health Study. J. Psychosom. Res., 2009b, 66: 67–74.
202. Smith, M. T., Perlis, M. L., Park, A. et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am. J. Psychiatry, 2002, 159: 5–11.
203. Sofi, F., Cesari, F., Casini, A., Macchi, C., Abbate, R. and Gensini, G. F. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur. J. Prev. Cardiol., 2014, 21: 57–64.
204. Spiegelhalder, K., Backhaus, J. and Riemann, D. Schlafstörungen (Fortschritte der Psychotherapie). Hogrefe, Göttingen, 2011.
205. Spielman, A. J., Caruso, L. S. and Glovinsky, P. B. A behavioral perspective on insomnia treatment. Psychiatr. Clin. North Am., 1987, 10: 541–553.
206. Stranks, E. K. and Crowe, S. F. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J. Clin. Exp. Neuropsychol., 2014, 36: 691–700.
207. Sun, Y., Lin, C. C., Lu, C. J., Hsu, C. Y. and Kao, C. H. Association between zolpidem and suicide: a nationwide population-based case-control study. Mayo Clin. Proc., 2016a, 91: 308–315.
208. Sun, Y. J., Yuan, J. M. and Yang, Z. M. Effectiveness and safety of moxibustion for primary insomnia: a systematic review and meta-analysis. BMC Compliment. Altern. Med., 2016b, 16: 217.
209. Sweetman, A., Lack, L. C., Catcheside, P. G. et al. Clinical review – developing a successful treatment for co-morbid insomnia and sleep apnoea. Sleep Med. Rev., 2017, 33: 28–38.
210. Tang, N. K., Lereya, S. T., Boulton, H., Miller, M. A., Wolke, D. and Cappuccio, F. P. Nonpharmacological treatments of insomnia for long-term painful conditions: a systematic review and meta-analysis of patient-reported outcomes in randomized controlled trials. Sleep, 2015, 38: 1751–1764.
211. Terhune, D. B., Cleeremans, A., Raz, A. and Lynn, S. J. Hypnosis and top-down regulation of consciousness. Neurosci Biobehav Rev. 2017 Feb 4. pii: S0149-7634(16)30633–9. doi: 10.1016/j.neubiorev.2017.02.002. [Epub ahead of print] Review.
212. Thiart, H., Ebert, D. D., Lehr, D. et al. Internet-based cognitive behavioral therapy for insomnia: a health economic evaluation. Sleep, 2016, 10: 1769–1778.
213. Thompson, W., Quay, T. A. W., Rojas-Fernandez, C. and Farrell, B. Atypical antipsychotics for insomnia: a systematic review. Sleep Med., 2016, 22: 13–17.
214. Tom, S. E., Wickwire, E. M., Park, Y. and Albrecht, J. S. Nonbenzodiazepine sedative hypnotics and risks of fall-related injury. Sleep, 2016, 39: 1009–1014.
215. Trauer, J. M., Qian, M. Y., Doyle, J. S., Rajaratnam, S. M. and Cunnington, D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann. Intern. Med., 2015, 163: 191–204.
216. Uchimura, N., Kamijo, A. and Takase, T. Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study. Ann. Gen. Psychiatry, 2012, 11: 15.
217. Uhlenhuth, E. H., Balter, M. B., Ban, T. A. and Yang, K. International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. J. Clin. Psychopharmacol., 1999, 19: 23S–29S.
218. Van de Straat, V. and Bracke, P. How well does Europe sleep? A cross-national study of sleep problems in European older adults. Int. J. Public Heath, 2015, 60: 643–650.
219. Van Maanen, A., Meijer, A. M., van der Heijden, K. B. and Oort, F. J. The effects of light therapy on sleep problems: a systematic review and meta-analysis. Sleep Med. Rev., 2016, 29: 52–62.
220. Van Straten, A. and Cuijpers, P. Self-help therapy for insomnia: a meta-analysis. Sleep Med. Rev., 2009, 13: 61–71.
221. Vande Griend, J. P. and Anderson, S. L. Histamine-1 receptor antagonism for treatment of insomnia. J. Am. Pharm. Assoc., 2012, 52: e210–e219.
222. Verbeek, I. and van de Laar, M. Behandeling van Langdurige Slapeloosheid. Springer Media, Bohn Stafleu van Loghum, Brussels, 2014.
223. Verster, J. C., Veldhuijzen, D. S., Patat, A., Olivier, B. and Volkerts, E. R. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr. Drug Saf., 2006, 1: 63–71.
224. Vgontzas, A. N., Fernandez-Mendoza, J., Liao, D. and Bixler, E. O. Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder. Sleep Med. Rev., 2013, 17: 241–254.
225. Voinescu, B. I. and Szentágotai, A. Categorical and dimensional assessment of insomnia in the general population. J. Cogn. Behav. Psychother., 2013, 13: 197–209.
226. Voshaar, R. C., Couvée, J. E., Van Balkom, A. J., Mulder, P. G. and Zitman, F. G. Strategies for discontinuing long-term benzodiazepine use. Br. J. Psychiatry, 2006, 189: 213–220.
227. Walsh, J. K., Krystal, A. D., Amato, D. A. et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep, 2007, 30: 959–968.
228. Wang, F., Eun-Kyoung Lee, O., Feng, F. et al. The effect of meditative movement on sleep quality: a systematic review. Sleep Med. Rev., 2016, 30: 43–52.
229. Winkler, A. and Rief, W. Effect of placebo conditions on polysomnographic parameters in primary insomnia: a meta-analysis. Sleep, 2015, 38: 925–931.
230. Winkler, A., Auer, C., Doering, B. K. and Rief, W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs, 2014, 28: 799–816.
231. Wittchen, H. U., Krause, P., Höfler, M. et al. NISAS-2000: nationwide insomnia screening and awareness study. Prevalence and interventions in primary care. Fortschr. Med. Orig., 2001, 119: 9–19.
232. Wittchen, H. U., Jacobi, F., Rehm, J. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol., 2011, 21: 655–679.
233. Wu, J. Q., Appleman, E. R., Salazar, R. D. and Ong, J. C. Cognitive behavioral therapy for insomnia comorbid with psychiatric and medical conditions: a meta-analysis. JAMA Intern. Med., 2015a, 175: 1461–1472.
234. Wu, W. W., Kwong, E., Lan, X. Y. and Jiang, X. Y. The effect of meditative movement intervention on quality of sleep in the elderly: a systematic review and meta-analysis. J. Altern. Complement. Med., 2015b, 21: 509–519.
235. Yaffe, K., Falvey, C. M. and Hoang, T. Connections between sleep and cognition in older adults. Lancet Neurol., 2014, 13: 1017–1028.
236. Ye, Y. Y., Zhang, Y. F., Chen, J. et al. Internet-based cognitive behavioral therapy for insomnia (ICBT-i) improves comorbid anxiety and depression – a meta-analysis of randomized controlled trials. PLoS ONE, 2015, 10: e0142258.
237. Yeung, W. F., Chung, K. F., Yung, K. P. and Ng, T. H. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med. Rev., 2015, 19: 75–83.
238. Yeung, W. F., Chunbg, K. F., Poon, M. M. K., Ho, F. Y. H., Zhang, S. P., Zhang, Z. J., Ziea, E. and Wong, T. Acupressure, reflexology, and auricular acupressure for insomnia: a sytematic review of randomized controlled trials. Sleep Med, 2012, 13: 971–984.
239. Zachariae, R., Lyby, M. S., Ritterband, L. M. and O'Toole, M. S. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia – a systematic review and meta-analysis of randomized controlled trials. Sleep Med. Rev., 2017, in press
240. Zhang, W. and Wing, Y. K. Sex differences in insomnia: a meta-analysis. Sleep, 2006, 29: 85–93.
241. Zhang, W., Chen, X. Y., Su, S. W. et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol. Sci., 2016, 37: 57–65.